Here they are...the 10 most widely-read stories on TheStreet.com now

Stocks Face Early Weakness
Robert Holmes
Stocks pulled back Tuesday as Dell's earnings squeeze zapped any
residual momentum left over from two strong sessions.


FOMC Set to Play the Dozens
Nick Godt

The Federal Open Market Committee is widely expected to tighten
another quarter-point Tuesday, marking the 12th straight meeting of
"measured pace" rate hikes. But while markets have become accustomed
to the metronome-like predictability of Fed policy, things have
changed since the Fed's last hike on Sept. 20. Most notably, the
appointment of Ben Bernanke to replace Alan Greenspan as Fed chairman
has inevitably fueled a debate about the future of monetary policy
after Greenspan steps down Jan. 31.

Tuning In on Sirius
Scott Moritz

Sirius hit the gas on retail sales last month. But come Tuesday,
investors will be checking the fuel tank. The New York satellite radio
shop is expected to deliver a third- quarter financial report before
the market opens, and all eyes will be on the price of user gains. A
big subscriber growth number used to be the only pill Wall Street
needed to quell its anxiety over mounting losses at Sirius and rival
XM Satellite Radio. But as XM's report last week of surging costs
showed, investors are now counting on seeing a little less red ink. XM
shares have fallen 20% this month on fears of widening losses.


At Teva, the Story Is Still Being Written
Robert Steyer

When it comes to pharmaceutical ubiquity, you can't beat or ignore
Teva Pharmaceutical. Last Thursday, shareholders approved a $7.4
billion takeover of generic-drug rival Ivax. If the Federal Trade
Commission endorses the deal, Teva will reclaim its title as the
world's biggest generic- drug maker, which it recently relinquished to
the Sandoz unit of Novartis. The previous week, Teva won a court
battle involving the Bristol-Myers Squibb cholesterol drug Pravachol
and signed a tentative agreement with Wyeth settling a patent suit for
the antidepressant Effexor XR. And this month, Teva is expected to
begin selling a generic version of Pfizer's big antibiotic Zithromax.
That's only part of the Teva story.

High Anxiety at Time Warner
Sandy Brown
The Internet bubble is long gone, but AOL talk continues to dominate
the agenda at Time Warner. The New York media giant is due to post
third-quarter earnings Wednesday morning. With investors tapping their
collective foot, Time Warner's board met last Thursday to discuss
America Online. A decision on AOL's strategic course isn't imminent,
according to sources, but a new heading could be set within weeks. In
the meantime, the company's slow growth continues to elicit groans.
Analysts polled by Thomson First Call expect Time Warner to post
earnings of 18 cents a share on $10.38 billion in revenue. That points
to year-over-year revenue growth of just 4.2% and compares with a
year-ago profit of 15 cents a share on revenue of just under $10
billion.

Daily Investing Tip
'Mad Money' Recap: Silicon Rally

Evergreen Solar is profitable and is expanding its manufacturing
capabilities with a subsidized plant in Germany. The company has
secured its silicon needs through 2006, so it will not be hurt by the
current shortage. The Street expects revenue of $100 million in 2007.
What's more, Evergreen is expected to earn 50 cents per share in 2008.
You're paying 16 times [earnings] that? ESLR has 40% growth. That is
faster than Google, so it deserves a higher multiple. Evergreen's
stock could double. However, Evergreen's stock is very volatile and it
could take a beating when it announces quarterly results Friday --
even if the numbers are good.
-- James Cramer, TheStreet.com



Jeff Cooper
Parsing an Important Market Clue
Once again, 1210 is an important line in the sand for the market in
the short term.

James J. Cramer
Stocks Bounce Off Sellers' Finish
A word from brokers about the end of tax-gain selling season is most
likely what's behind the lift in some stocks.